Tagged with R

Switzerland Catherine Pickering, CEO of iOnctura, explains how her agile Swiss biotech is pioneering precision small-molecule therapies to overcome tumour resistance, with a focus on lead asset – roginolisib and a pipeline built on novel scientific mechanisms. She discusses the company’s evolution from seed funding through Series B and the role…

Switzerland Mads Stoustrup, co-founder and CEO of Azento Health, shares his journey from 22 years at Novo Nordisk to launching a science-driven startup focused on supporting patients undergoing GLP-1 treatment for obesity. Azento Health develops clinically backed probiotic supplements, designed to reduce gastrointestinal side effects and improve treatment adherence. Backed by…

Switzerland The transformation of CEVA Logistics’ healthcare strategy – led by industry veteran Eric ten Kate – is unfolding with quiet precision and sharp focus. As part of the CMA CGM Group and with a mandate rooted in operational excellence, digital intelligence, and regional depth, CEVA is redefining its position in…

Denmark Flemming Sonne, CEO of Amgros, Denmark’s central pharmaceutical procurement organization for hospital medicines, outlines the organisation’s evolving role in ensuring affordable and sustainable access to medicines. In this interview, Sonne discusses Denmark’s forward-thinking approach to supply chain resilience, the integration of ATMPs and innovative access models, and the increasing convergence…

Switzerland Michele Ravara brings a global perspective and deep strategic experience to his role as general manager of AbbVie Switzerland, following nearly a decade leading the Oncology Business from a global standpoint in the US. In just over two months, he has embraced Switzerland’s complex healthcare ecosystem and diverse talent landscape,…

Italy Banking on three key therapeutic areas, including a newly established rare disease franchise, the Italian midcap Chiesi has pursued a sweeping transformation in recent years. In its reboot efforts, the company has not only made significant R&D investments, but pursued key M&A and partnership deals, and aimed for global expansion.…

Global 2023 may have been a breakthrough year for cell and gene therapies with the FDA approving a record of seven novel treatments, but 2024 did not fall behind in the number of greenlit therapies. With seven new approvals and three expanded indications, the cell and gene therapies authorized by the…

USA As the search for effective Alzheimer’s treatments continues to evolve, Annovis Bio is taking a distinct approach with buntanetap, a novel oral candidate designed to intervene more broadly in disease progression. In this interview, Chief Business Officer Mark White discusses the company’s clinical learnings, operational discipline, and the realities of…

Global As the neuroscience field gains unprecedented momentum, Roche is taking a leading role in redefining how neurodegenerative diseases like Alzheimer’s are understood, diagnosed, and treated. Dr Azad Bonni, Senior Vice President and Global Head of Neuroscience and Rare Diseases at Roche’s Pharma Research and Early Development (pRED), brings a unique…

Puerto Rico Glorimar Torres, with over 33 years in the pharmaceutical industry, has had a diverse career, starting as a sales representative in Puerto Rico and progressing through key roles at companies like Merck & Co. (MSD), Bristol Myers Squibb, Pfizer, and GlaxoSmithKline (GSK) before joining Amgen. At Amgen, she played a…

Hong Kong Few biotech companies emerge with both scientific depth and a clear sense of direction. Innorna, founded by Dr Linxian Li after years spent refining RNA delivery systems in academic settings, is one of them. What began as a technical platform matured through a pandemic-era proof of concept and now moves…

Saudi Arabia Amidst the hype of Saudi Arabia’s embrace of innovative therapies and technologies, the concepts of access and affordability can often be forgotten. However, the Saudi government remains the dominant healthcare payer in the country and, with medicines already consuming over 20 percent of national healthcare spending, is putting increasing emphasis…